Cytosorbents Reports Q3 2026 Revenue Growth and Improved Financial Position
Cytosorbents (CTSO) reported third-quarter 2026 revenue of $9.7 million, a 3% year-over-year increase driven primarily by growth in distributor and strategic partner sales. The company demonstrated significant operational improvements, including an 11% decline in operating expenses due to headcount reductions and tighter cost controls. Notably, the company achieved positive operating cash flow of $43,000 (excluding restructuring payments), marking a major financial milestone. Despite a 20% revenue decline in Germany following restructuring, international direct sales grew by 4%. The company's gross margin rose to 75%, up 200 basis points from the previous quarter. While management cautioned that reaching break-even may be inconsistent due to order timing, the firm is focused on satisfying Nasdaq listing requirements and completing debt restructuring by the end of 2026.
Topics: cash flow positive cost reduction margin expansion revenue growth